DAWN Day One Biopharmaceuticals Inc

Price (delayed)

$15.92

Market cap

$1.39B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.51

Enterprise value

$1.12B

Highlights
The debt has dropped by 58% year-on-year and by 26% since the previous quarter
DAWN's net income is down by 33% year-on-year and by 11% since the previous quarter
The quick ratio has contracted by 23% YoY and by 14% from the previous quarter

Key stats

What are the main financial stats of DAWN
Market
Shares outstanding
87.39M
Market cap
$1.39B
Enterprise value
$1.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$208.94M
EBITDA
-$208.53M
Free cash flow
-$170.8M
Per share
EPS
-$2.51
Free cash flow per share
-$1.97
Book value per share
$3.4
Revenue per share
$0
TBVPS
$3.77
Balance sheet
Total assets
$326.65M
Total liabilities
$29.84M
Debt
$300,000
Equity
$296.81M
Working capital
$296.2M
Liquidity
Debt to equity
0
Current ratio
10.93
Quick ratio
10.66
Net debt/EBITDA
1.3
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-53.3%
Return on equity
-57.3%
Return on invested capital
-157.8%
Return on capital employed
-70.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DAWN stock price

How has the Day One Biopharmaceuticals stock price performed over time
Intraday
7.06%
1 week
-0.56%
1 month
16.37%
1 year
31.57%
YTD
9.04%
QTD
15.53%

Financial performance

How have Day One Biopharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$226.98M
Net income
-$208.94M
Gross margin
N/A
Net margin
N/A
The operating income has decreased by 38% YoY and by 10% from the previous quarter
DAWN's net income is down by 33% year-on-year and by 11% since the previous quarter

Growth

What is Day One Biopharmaceuticals's growth rate over time

Valuation

What is Day One Biopharmaceuticals stock price valuation
P/E
N/A
P/B
4.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 10% YoY and by 6% QoQ
The stock's P/B is 33% more than its last 4 quarters average of 3.3
The company's equity fell by 14% QoQ

Efficiency

How efficient is Day One Biopharmaceuticals business performance
The ROIC has plunged by 88% YoY and by 58% from the previous quarter
Day One Biopharmaceuticals's ROE has decreased by 26% YoY and by 11% from the previous quarter
The ROA is down by 24% year-on-year and by 10% since the previous quarter

Dividends

What is DAWN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DAWN.

Financial health

How did Day One Biopharmaceuticals financials performed over time
Day One Biopharmaceuticals's total liabilities has increased by 29% YoY
Day One Biopharmaceuticals's current ratio has decreased by 23% YoY and by 14% QoQ
The debt is 100% smaller than the equity
The debt has dropped by 58% year-on-year and by 26% since the previous quarter
The company's equity fell by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.